Prot#GS-US-419-4015: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn’s Disease (SBCD)

Project: Research project

Project Details

StatusFinished
Effective start/end date5/30/18 → 5/30/21

Funding

  • Quintiles, Inc. (GS-US-419-4015)
  • Gilead Sciences, Inc. (GS-US-419-4015)